Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
ProQR Therapeutics NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PRQR
Nasdaq
8731
https://www.proqr.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for ProQR Therapeutics NV
ProQR Therapeutics Full Year 2023 Earnings: Misses Expectations
- Mar 14th, 2024 10:14 am
ProQR Announces Year End 2023 Operating and Financial Results
- Mar 13th, 2024 11:00 am
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
- Feb 15th, 2024 12:00 pm
ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
- Jan 19th, 2024 12:00 pm
While institutions invested in ProQR Therapeutics N.V. (NASDAQ:PRQR) benefited from last week's 12% gain, individual investors stood to gain the most
- Jan 15th, 2024 11:25 am
ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
- Jan 5th, 2024 12:00 pm
Is ProQR (PRQR) Stock a Solid Choice Right Now?
- Dec 28th, 2023 1:44 pm
ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets
- Dec 8th, 2023 12:30 pm
ProQR Announces Third Quarter 2023 Operating and Financial Results
- Nov 7th, 2023 12:00 pm
ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing
- Nov 6th, 2023 12:00 pm
ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference
- Sep 28th, 2023 12:00 pm
ProQR Therapeutics Provides Update on Ophthalmic Assets
- Sep 27th, 2023 11:00 am
ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference
- Sep 7th, 2023 12:00 pm
ProQR Therapeutics N.V.'s (NASDAQ:PRQR) top owners are retail investors with 50% stake, while 31% is held by institutions
- Aug 8th, 2023 10:37 am
ProQR Announces Second Quarter 2023 Operating and Financial Results
- Aug 3rd, 2023 11:00 am
ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets
- Aug 1st, 2023 11:00 am
ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit
- Jul 6th, 2023 11:00 am
ProQR Therapeutics' (NASDAQ:PRQR) investors will be pleased with their impressive 109% return over the last year
- Jun 28th, 2023 10:02 am
ProQR Therapeutics N.V. (NASDAQ:PRQR) Could Be Less Than A Year Away From Profitability
- May 18th, 2023 11:02 am
ProQR Announces First Quarter 2023 Operating and Financial Results
- May 16th, 2023 11:00 am
Scroll